CliffBio
small molecule

ERYTHROCIN STEARATE

ERYTHROMYCIN STEARATE

Loss of exclusivity—loss of exclusivity
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYTHROCIN STEARATE
Active ingredientERYTHROMYCIN STEARATE
StrengthEQ 500MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
Marketing statusDISCN

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.